Stealth BioTherapeutics Corp (MITO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.2525 |
| Open | 0.2401 |
| Bid | 0.2360 x 3100 |
| Ask | 0.2720 x 1000 |
| Day's Range | 0.2331 - 0.2601 |
| 52 Week Range | 0.1620 - 1.5800 |
| Volume | |
| Avg. Volume | 2,658,508 |
| Market Cap | 18.019M |
| Beta (5Y Monthly) | 2.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9240 |
| Earnings Date | Nov 11, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.53 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MITO
Related Research
- Stealth BioTherapeutics Corp.Analyst Report: Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).RatingFair ValueEconomic Moat10 days agoMorningstar
- PR Newswire
Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding Proposal
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today that its Board of Directors (the "Board") has received a preliminary non-binding proposal letter dated June 24, 2022 (the "Proposal Letter") from Morningside Venture (I) Investments Ltd. for itself and on behalf of its affiliates ("Morningside") and J. Wood Capital Advi
- PR Newswire
Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced its plan to meet with the U.S. Food & Drug Administration (FDA) Division of Cardiology and Nephrology (DCN) to discuss new clinical data that may inform a potential new drug application (NDA) submission for the treatment of Barth Syndrome.
- GlobeNewswire
Healthcare Breakthroughs: NVAX, MITO, LMLLF, NMLSF; Life Sciences Leaders Report Latest Advances in Vaccines, Novel Therapeutics for Autism, Neurodegenerative, Oncology, and Glaucoma
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Novavax (NASDAQ: NVAX), Stealth BioTherapeutics (NASDAQ: MITO) and PharmaDrug (OTC: LMLLF) (CSE: PHRX). As the global pharma market surpasses $1.3 trillion dollars (Statista), emerging technologies and healthcare research innovations are unleashing new exponenti
